Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of REGN22530 in Participants With Primary Open Angle Glaucoma or Ocular Hypertension

NCT07675824 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT07675824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07675824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of REGN22530 in Participants With Primary Open Angle Glaucoma or Ocular Hypertension
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 8, 2026
Completion date
December 6, 2029
Enrollment
271 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension (oht), primary open angle glaucoma (poag)